Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypertension and left-ventricular hypertrophy

F H Messerli1, F C Aepfelbacher

  • 1Department of Internal Medicine, Ochsner Clinic, New Orleans, Louisiana, USA.

Cardiology Clinics
|November 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Urocortin 2 - a protective effect in hypertension?

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2023
Same author

In vitro fertilization exacerbates stroke size and neurological disability in wildtype mice.

International journal of cardiology·2021
Same author

More SPRINT controversy.

Journal of internal medicine·2017
Same author

Optimal blood pressure targets in 2014 - Does the guideline recommendation match the evidence base?

Hipertension y riesgo vascular·2015
Same author

Cardioprotection with beta-blockers: myths, facts and Pascal's wager.

Journal of internal medicine·2009
Same author

Beta-blockers as fourth-line therapy for hypertension: stay the course.

International journal of clinical practice·2009
Same journal

At the Edge of the Possible: A New Standard for Cardiovascular Critical Care.

Cardiology clinics·2026
Same journal

End-of-Life Care in the Cardiovascular Intensive Care Unit.

Cardiology clinics·2026
Same journal

Strategies to Reduce Failure to Rescue after Cardiac Surgery.

Cardiology clinics·2026
Same journal

Embracing Enhanced Recovery After Cardiac Surgery Program.

Cardiology clinics·2026
Same journal

Post-Heart Transplantation Intensive Care Unit Recovery: A Phase-Based Approach.

Cardiology clinics·2026
Same journal

A Practical Guide to Intensive Care Unit Management after Left Ventricular Assist Device Implantation.

Cardiology clinics·2026
See all related articles

Left-ventricular hypertrophy (LVH) is a major risk factor for cardiovascular events. Antihypertensive therapy can reduce LVH, but further studies are needed to confirm clinical benefits.

Area of Science:

  • Cardiology
  • Hypertension Research

Background:

  • Left-ventricular hypertrophy (LVH) is the primary cardiac manifestation of hypertension.
  • LVH is a significant risk factor for cardiovascular events, including myocardial infarction and heart failure.
  • Increased myocardial mass in LVH impairs cardiac function and oxygen supply.

Purpose of the Study:

  • To review the causes and consequences of left-ventricular hypertrophy.
  • To discuss the role of antihypertensive therapy in managing LVH.
  • To highlight the need for further research on the clinical benefits of LVH reduction.

Main Methods:

  • Literature review of studies on hypertension and left-ventricular hypertrophy.
  • Analysis of risk factors contributing to LVH, both hemodynamic and nonhemodynamic.

Related Experiment Videos

  • Evaluation of the impact of antihypertensive therapy on LVH.

    • Main Results:

    • Hypertension is the leading cause of LVH, a potent predictor of cardiovascular events.
    • Obesity, age, and valvular disease also contribute to LVH.
    • Dietary factors like salt intake and alcohol, along with neurohormones, influence left-ventricular mass.
    • Antihypertensive therapies show potential in reducing LVH and its associated risks.

    Conclusions:

    • LVH significantly increases cardiovascular morbidity and mortality.
    • While antihypertensive therapy can reduce LVH, further epidemiological studies are required to validate its clinical benefits.
    • Understanding and managing LVH is crucial for preventing cardiovascular events.